Profile: AMAG Pharmaceuticals Inc (AMAG.OQ)
7 Mar 2014
AMAG Pharmaceuticals, Inc., incorporated on November 9, 1981, is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection for Intravenous (IV), used to treat iron deficiency anemia (IDA), in adult patients with chronic kidney disease (CKD), and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucositis. The Company sells Feraheme to authorized wholesalers and specialty distributors, who in turns, sell Feraheme to healthcare providers who administer Feraheme primarily within hospitals, hematology and oncology centers, and nephrology clinics. Its principal source of revenue is from the sale of Feraheme (ferumoxytol) Injection for intravenous (IV).
The Company markets and sells Feraheme in both the dialysis and non-dialysis CKD markets, including to nephrologists, hematologists, dialysis organizations, hospitals and other end-users who treat patients with CKD. There are two methods used to treat IDA in CKD patients: oral iron supplements and IV iron. Oral iron supplements are often not absorbed well by the gastrointestinal tract and frequently have unpleasant side effects, such as constipation, diarrhea, and cramping, which can cause patients to stop taking their medication. In addition, it can take an extended time for hemoglobin levels to improve the initiation of oral iron treatment.
Venofer is administered as a slow intravenous injection over 2 to 5 minutes in doses of 100 to 200 milligrams, thus requiring 5 to 10 physician visits to reach a standard one gram therapeutic course. INFeD and Dexferrum are administered as a slow push in 100 milligram doses and also require up to 10 physician visits to receive a standard one gram therapeutic course. Feraheme is administered as a 510 milligram injection.
The Company competes with Fresenius Medical Care North America, American Regent Laboratories, Inc., Sanofi-Aventis U.S. LLC and Watson Pharmaceuticals, Inc.
AMAG Pharmaceuticals Inc
1100 Winter Street
WALTHAM MA 02451